Luna, A; Pérez-Lamas, L; Boque, C; Giraldo, P; Xicoy, B; Ruiz-Nuno, C; Moreno-Vega, M; Álvarez-Larran, A; Salamanca, A; García-Noblejas, A; Vall-Llovera, F; Villalon, L; De-Las-Heras, N; Ramila, E; Pérez-Encinas, M; Cuevas, B; Pérez-López, R; Sánchez-Guijo, F; Jiménez-Velasco, A; Lakhwani, S; Felipe-Casado, L; Rosell, A; Escola, A; Fernández, MJ; García-Hernández, C; Cervero, C; Mora, E; Sagues, M; Suárez-Varela, S; Velez, P; Carrascosa-Mastell, P; Bitaube, RF; Serrano, L; Cortes, M; Vera-Goni, JA; Steegmann, JL; García-de-Soria, VGómez; Alonso-Domínguez, JM; Colorado-Araujo, M; Paz-Coll, A; Hernández-Boluda, JC; García-Gutierrez, V
(Springer, 2022-10)
Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US Federal Drug Administration, has demonstrated ...